

<b>Project Title</b>	<b>International leadership in precision medicine clinical studies</b>
<b>Principal Investigator</b>	<b>Jean-Claude Tardif</b>
<b>Principal Institution</b>	Montreal Heart Institute
<b>Summary</b>	
<p>Cardiovascular diseases cause several extracardiac complications and have risk factors similar to those of several cancers. The initiative will strengthen the collaboration and complementarity of two important Quebec infrastructures in the field of precision medicine clinical studies, the Montreal Health Innovations Coordinating Center (MHICC) and the University of Montreal's Beaulieu-Saucier Pharmacogenomics Center. In addition, it will consolidate the partnership of six complementary Quebec platforms in clinical research, pharmacogenomics, biomarker studies, artificial intelligence and neuroimaging. Interdisciplinary experts from four universities will combine their efforts, as well as a network of 25 Quebec hospitals and their clinicians for the conduct of clinical studies in precision medicine. The initiative will also strengthen the interactions of these academic institutions with Quebec biotech companies, including DalCor Pharmaceuticals, PharmaScience and global biopharmaceutical companies including AstraZeneca and Bayer. This major initiative has the potential to make Quebec a hub of cardiovascular and extracardiac precision medicine clinical trials, thus making it stand out internationally.</p>	